Massachusetts Attorney General Andrea Joy Campbell has made headlines again by securing $17.85 million in settlements with pharmaceutical giants Lannett Company, Inc. and Bausch Health, as reported Mass.gov. These agreements resolve allegations that the companies engaged in price-fixing conspiracies affecting the cost of essential generic prescription drugs. Eligible Massachusetts consumers may qualify for restitution; information can be sought by calling toll-free at 1-866-290-0182, emailing [email protected], or visiting www.AGGenericDrugs.com.
As part of the settlements, Lannett and Bausch have committed to a series of internal reforms, purportedly, to encourage competition and ensure adherence to antitrust laws, they also to be cooperating with ongoing litigation against numerous other pharmaceutical entities, in a comprehensive push towards accountability within the industry. These settlements follow prior agreements with Apotex and Heritage totaling $49.1 million, emphasizing AG Campbell's continuing resolve to combat corporate malfeasance.
In the same vein, AG Campbell joined a multistate coalition in filing a fresh lawsuit against Novartis and its generic subsidiary Sandoz over alleged price-fixing activities; this complaint involves 31 different generic drugs and integrates claims that Novartis attempted to insulate itself from liability via strategic corporate maneuvering. The Massachusetts Attorney General's office, spearheaded by Chief Anthony Mariano and his team, remains at the forefront of this legal challenge seeking to dismantle the purportedly unfair pricing schemes that obstruct drug affordability.
The recent action against Novartis and Sandoz adds to a string of antitrust complaints initiated since 2017, with the Massachusetts coalition aggressively pursuing pharmaceutical companies accused of colluding to inflate drug prices and minimize competition, this sustained legal effort reflects AG Campbell's commitment to protecting consumer access to affordable medications including a pertinent 2025 lawsuit against insulin producers.
Nearly all states and territories have unified under AG Campbell's initiative, signaling a widespread recognition of the urgency to counteract alleged illicit practices within the pharmaceutical industry.
